Parnax Lab (BOM:506128) 3-Year Revenue Growth Rate : 15.80% (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Parnax Lab 3-Year Revenue Growth Rate?

Parnax Lab's Revenue per Share for the three months ended in Mar. 2024 was ₹40.35.

During the past 12 months, Parnax Lab's average Revenue per Share Growth Rate was 8.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 15.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 8.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 6.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Parnax Lab was 15.80% per year. The lowest was -5.10% per year. And the median was 9.50% per year.

Competitive Comparison of Parnax Lab's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Parnax Lab's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnax Lab's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnax Lab's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Parnax Lab's 3-Year Revenue Growth Rate falls into.

Parnax Lab 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Parnax Lab (BOM:506128) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Parnax Lab 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Parnax Lab's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnax Lab (BOM:506128) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnax Lab Ltd (BOM:506128) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

N/A

Address

104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022

Website

https://www.naxparlab.com

Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.

Parnax Lab (BOM:506128) Headlines

No Headlines